751.66
Schlusskurs vom Vortag:
$777.59
Offen:
$768.845
24-Stunden-Volumen:
25.65M
Relative Volume:
1.33
Marktkapitalisierung:
$1.91T
Einnahmen:
$214.96B
Nettoeinkommen (Verlust:
$70.59B
KGV:
27.33
EPS:
27.5066
Netto-Cashflow:
$48.25B
1W Leistung:
+12.90%
1M Leistung:
+31.86%
6M Leistung:
+26.35%
1J Leistung:
+0.37%
Meta Platforms Inc Stock (META) Company Profile
Firmenname
Meta Platforms Inc
Sektor
Telefon
650-543-4800
Adresse
1 META WAY, MENLO PARK
Compare META vs GOOGL, GOOG, SPOT, DASH
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
META
Meta Platforms Inc
|
751.66 | 1.91T | 214.96B | 70.59B | 48.25B | 27.51 |
|
GOOGL
Alphabet Inc
|
343.92 | 4.21T | 446.32B | 244.21B | 53.27B | 19.91 |
|
GOOG
Alphabet Inc
|
341.08 | 4.17T | 446.32B | 244.21B | 53.27B | 19.91 |
|
SPOT
Spotify Technology Sa
|
510.01 | 104.85B | 20.32B | 3.16B | 3.82B | 12.55 |
|
DASH
Doordash Inc
|
193.36 | 83.78B | 14.72B | 923.00M | 1.75B | 2.0994 |
Meta Platforms Inc Stock (META) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-25 | Bestätigt | Canaccord Genuity | Buy |
| 2026-09-25 | Bestätigt | Deutsche Bank | Buy |
| 2026-09-25 | Bestätigt | Piper Sandler | Overweight |
| 2026-09-25 | Bestätigt | TD Cowen | Buy |
| 2026-09-23 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2026-09-21 | Bestätigt | Wells Fargo | Overweight |
| 2026-09-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2026-08-27 | Bestätigt | Rosenblatt | Buy |
| 2026-08-27 | Bestätigt | Truist | Buy |
| 2026-07-30 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2026-07-16 | Fortgesetzt | Wedbush | Neutral |
| 2026-07-10 | Bestätigt | Citizens | Mkt Outperform |
| 2026-07-07 | Hochstufung | Erste Group | Hold → Buy |
| 2026-06-02 | Hochstufung | Arete | Neutral → Buy |
| 2026-05-20 | Bestätigt | Wells Fargo | Overweight |
| 2026-05-05 | Bestätigt | Mizuho | Outperform |
| 2026-04-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-04-10 | Bestätigt | Wolfe Research | Outperform |
| 2026-04-09 | Bestätigt | Rosenblatt | Buy |
| 2026-04-02 | Herabstufung | Erste Group | Buy → Hold |
| 2026-03-30 | Bestätigt | Morgan Stanley | Overweight |
| 2026-03-05 | Herabstufung | Arete | Buy → Neutral |
| 2026-03-05 | Hochstufung | Erste Group | Hold → Buy |
| 2026-02-23 | Bestätigt | Wells Fargo | Overweight |
| 2026-01-29 | Bestätigt | Canaccord Genuity | Buy |
| 2026-01-29 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2026-01-29 | Bestätigt | Deutsche Bank | Buy |
| 2026-01-29 | Bestätigt | Evercore ISI | Outperform |
| 2026-01-29 | Bestätigt | Guggenheim | Buy |
| 2026-01-29 | Bestätigt | JP Morgan | Overweight |
| 2026-01-29 | Bestätigt | Jefferies | Buy |
| 2026-01-29 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2026-01-29 | Bestätigt | Mizuho | Outperform |
| 2026-01-29 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2026-01-29 | Bestätigt | Morgan Stanley | Overweight |
| 2026-01-29 | Bestätigt | Piper Sandler | Overweight |
| 2026-01-29 | Bestätigt | Pivotal Research Group | Buy |
| 2026-01-29 | Bestätigt | Robert W. Baird | Outperform |
| 2026-01-29 | Bestätigt | Roth Capital | Buy |
| 2026-01-29 | Bestätigt | Stifel | Buy |
| 2026-01-29 | Bestätigt | UBS | Buy |
| 2026-01-29 | Bestätigt | Wedbush | Outperform |
| 2026-01-29 | Bestätigt | Wells Fargo | Overweight |
| 2026-01-29 | Bestätigt | Wolfe Research | Outperform |
| 2026-01-26 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2026-01-26 | Bestätigt | Raymond James | Strong Buy |
| 2026-01-26 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-23 | Bestätigt | Stifel | Buy |
| 2026-01-13 | Bestätigt | TD Cowen | Buy |
| 2026-01-12 | Bestätigt | Wells Fargo | Overweight |
| 2026-01-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2026-01-08 | Bestätigt | Guggenheim | Buy |
| 2025-12-04 | Hochstufung | Arete | Neutral → Buy |
| 2025-11-24 | Eingeleitet | BNP Paribas Exane | Outperform |
| 2025-11-10 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-30 | Bestätigt | Barclays | Overweight |
| 2025-10-30 | Bestätigt | Bernstein | Outperform |
| 2025-10-30 | Bestätigt | BofA Securities | Buy |
| 2025-10-30 | Bestätigt | Citigroup | Buy |
| 2025-10-30 | Bestätigt | JP Morgan | Overweight |
| 2025-10-30 | Bestätigt | Jefferies | Buy |
| 2025-10-30 | Bestätigt | Mizuho | Outperform |
| 2025-10-30 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2025-10-30 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-30 | Bestätigt | Piper Sandler | Overweight |
| 2025-10-30 | Bestätigt | Stifel | Buy |
| 2025-10-30 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2025-10-20 | Bestätigt | Oppenheimer | Outperform |
| 2025-10-07 | Bestätigt | Wells Fargo | Overweight |
| 2025-09-30 | Eingeleitet | Mizuho | Outperform |
| 2025-07-31 | Bestätigt | BMO Capital Markets | Market Perform |
| 2025-07-31 | Bestätigt | Bernstein | Outperform |
| 2025-07-31 | Bestätigt | BofA Securities | Buy |
| 2025-07-31 | Bestätigt | Citigroup | Buy |
| 2025-07-31 | Bestätigt | Citizens JMP | Mkt Outperform |
| 2025-07-31 | Bestätigt | JP Morgan | Overweight |
| 2025-07-31 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-07-31 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2025-07-31 | Bestätigt | Morgan Stanley | Overweight |
| 2025-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2025-07-31 | Bestätigt | Pivotal Research Group | Buy |
| 2025-07-31 | Bestätigt | TD Cowen | Buy |
| 2025-07-31 | Bestätigt | UBS | Buy |
| 2025-07-31 | Bestätigt | Wedbush | Outperform |
| 2025-07-31 | Bestätigt | Wells Fargo | Overweight |
| 2025-07-28 | Bestätigt | Guggenheim | Buy |
| 2025-07-16 | Bestätigt | Canaccord Genuity | Buy |
| 2025-07-03 | Hochstufung | Needham | Underperform → Hold |
| 2025-06-26 | Bestätigt | UBS | Buy |
| 2025-06-24 | Bestätigt | Citigroup | Buy |
| 2025-05-01 | Bestätigt | BofA Securities | Buy |
| 2025-05-01 | Bestätigt | Citigroup | Buy |
| 2025-05-01 | Bestätigt | Evercore ISI | Outperform |
| 2025-05-01 | Bestätigt | Goldman | Buy |
| 2025-05-01 | Bestätigt | Guggenheim | Buy |
| 2025-05-01 | Bestätigt | JP Morgan | Overweight |
| 2025-05-01 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-05-01 | Bestätigt | MoffettNathanson | Buy |
| 2025-05-01 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2025-05-01 | Bestätigt | Morgan Stanley | Overweight |
| 2025-05-01 | Bestätigt | Oppenheimer | Outperform |
| 2025-05-01 | Bestätigt | Piper Sandler | Overweight |
| 2025-05-01 | Bestätigt | Pivotal Research Group | Buy |
| 2025-05-01 | Bestätigt | Raymond James | Strong Buy |
| 2025-05-01 | Bestätigt | Rosenblatt | Buy |
| 2025-05-01 | Bestätigt | Roth Capital | Buy |
| 2025-05-01 | Bestätigt | Stifel | Buy |
| 2025-05-01 | Bestätigt | Truist | Buy |
| 2025-05-01 | Bestätigt | UBS | Buy |
| 2025-05-01 | Bestätigt | Wedbush | Outperform |
| 2025-04-14 | Bestätigt | Citigroup | Buy |
| 2025-04-10 | Bestätigt | Piper Sandler | Overweight |
| 2025-01-30 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2025-01-23 | Bestätigt | BofA Securities | Buy |
| 2025-01-22 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2025-01-06 | Bestätigt | Jefferies | Buy |
| 2025-01-03 | Bestätigt | Wolfe Research | Outperform |
| 2024-10-31 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2024-10-31 | Bestätigt | Pivotal Research Group | Buy |
| 2024-10-11 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-09 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2024-10-01 | Eingeleitet | Pivotal Research Group | Buy |
| 2024-09-30 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2024-09-10 | Eingeleitet | DA Davidson | Buy |
| 2024-09-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-01 | Bestätigt | BofA Securities | Buy |
| 2024-07-19 | Bestätigt | Oppenheimer | Outperform |
| 2024-07-16 | Eingeleitet | Wolfe Research | Outperform |
| 2024-07-10 | Bestätigt | TD Cowen | Buy |
| 2024-07-08 | Bestätigt | Wells Fargo | Overweight |
| 2024-07-01 | Bestätigt | Raymond James | Strong Buy |
| 2024-06-12 | Bestätigt | BMO Capital Markets | Market Perform |
| 2024-05-02 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2024-04-25 | Bestätigt | Oppenheimer | Outperform |
| 2024-04-15 | Bestätigt | Citigroup | Buy |
| 2024-04-11 | Bestätigt | Piper Sandler | Overweight |
| 2024-04-08 | Bestätigt | Oppenheimer | Outperform |
| 2024-04-04 | Bestätigt | Jefferies | Buy |
| 2024-02-02 | Bestätigt | Guggenheim | Buy |
| 2024-02-02 | Bestätigt | JMP Securities | Mkt Outperform |
| 2024-02-02 | Bestätigt | JP Morgan | Overweight |
| 2024-02-02 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-02-02 | Bestätigt | Mizuho | Buy |
| 2024-02-02 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2024-02-02 | Bestätigt | Morgan Stanley | Overweight |
| 2024-02-02 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-02 | Bestätigt | Piper Sandler | Overweight |
| 2024-02-02 | Bestätigt | ROTH MKM | Buy |
| 2024-02-02 | Bestätigt | Raymond James | Strong Buy |
| 2024-02-02 | Bestätigt | Robert W. Baird | Outperform |
| 2024-02-02 | Bestätigt | Seaport Research Partners | Buy |
| 2024-02-02 | Bestätigt | Stifel | Buy |
| 2024-02-02 | Bestätigt | Susquehanna | Positive |
| 2024-02-02 | Bestätigt | TD Cowen | Outperform |
| 2024-02-02 | Bestätigt | UBS | Buy |
| 2024-02-02 | Bestätigt | Wedbush | Outperform |
| 2024-02-02 | Bestätigt | Wells Fargo | Overweight |
| 2024-02-02 | Bestätigt | Wolfe Research | Outperform |
| 2024-01-23 | Bestätigt | Citigroup | Buy |
| 2024-01-17 | Bestätigt | Piper Sandler | Overweight |
| 2024-01-17 | Bestätigt | Wells Fargo | Overweight |
| 2024-01-09 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-20 | Fortgesetzt | Raymond James | Strong Buy |
| 2023-10-24 | Eingeleitet | Seaport Research Partners | Buy |
| 2023-08-22 | Eingeleitet | Wedbush | Outperform |
| 2023-08-01 | Bestätigt | Argus | Buy |
| 2023-07-28 | Hochstufung | China Renaissance | Hold → Buy |
| 2023-07-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-07-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-07-25 | Bestätigt | Mizuho | Buy |
| 2023-07-25 | Hochstufung | New Street | Neutral → Buy |
| 2023-07-19 | Bestätigt | Jefferies | Buy |
| 2023-07-19 | Bestätigt | Truist | Buy |
| 2023-07-17 | Bestätigt | Credit Suisse | Outperform |
| 2023-07-17 | Bestätigt | Goldman | Buy |
| 2023-07-17 | Bestätigt | JMP Securities | Mkt Outperform |
| 2023-07-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-07-12 | Bestätigt | Deutsche Bank | Buy |
| 2023-06-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-05-15 | Hochstufung | Loop Capital | Hold → Buy |
| 2023-04-27 | Bestätigt | Credit Suisse | Outperform |
| 2023-04-27 | Bestätigt | Deutsche Bank | Buy |
| 2023-04-27 | Bestätigt | Evercore ISI | Outperform |
| 2023-04-27 | Bestätigt | Goldman | Buy |
| 2023-04-27 | Bestätigt | Guggenheim | Buy |
| 2023-04-27 | Bestätigt | JMP Securities | Mkt Outperform |
| 2023-04-27 | Bestätigt | JP Morgan | Overweight |
| 2023-04-27 | Bestätigt | Mizuho | Buy |
| 2023-04-27 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2023-04-27 | Bestätigt | Morgan Stanley | Overweight |
| 2023-04-27 | Bestätigt | Oppenheimer | Outperform |
| 2023-04-27 | Bestätigt | Piper Sandler | Overweight |
| 2023-04-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2023-04-27 | Bestätigt | Raymond James | Outperform |
| 2023-04-27 | Bestätigt | Robert W. Baird | Outperform |
| 2023-04-27 | Bestätigt | Rosenblatt | Buy |
| 2023-04-27 | Bestätigt | Stifel | Buy |
| 2023-04-27 | Bestätigt | TD Cowen | Market Perform |
| 2023-04-27 | Bestätigt | Truist | Buy |
| 2023-04-27 | Bestätigt | Wolfe Research | Outperform |
Alle ansehen
Meta Platforms Inc Aktie (META) Neueste Nachrichten
Meta says it will run ads for ‘Musk’ documentary after all - TechCrunch
New Mexico Jury Rules Meta Misled State Residents About Data Privacy - Engadget
Guess Which Group of Stocks Is Back at an All-Time High? - The Motley Fool
Benzinga Bulls and Bears: Costco, KB Home, McDonald’s - Benzinga
Why semiconductor company AMD and Meta (and its Muse) had a good week - Detroit Free Press
Meta turned Muse into a viral hit. Now comes the hard part. - MarketWatch
Trading expert sets date when Meta stock will hit $1,000 - Finbold
Meta Lost a $219 Billion Verdict in New Mexico. The Math Behind It Is Wild. - Vocal
3,819 Meta Platforms, Inc. $META Shares Bought by Syon Capital LLC - MarketBeat
Meta Platforms, Inc. $META Shares Bought by TD Waterhouse Canada Inc. - MarketBeat
Knollwood Investment Advisory LLC Raises Holdings in Meta Platforms, Inc. $META - MarketBeat
5,418 Meta Platforms, Inc. $META Shares Purchased by Munich Reinsurance Co Stock Corp in Munich - MarketBeat
Meta Platforms, Inc. $META Stock Acquired by BAM Wealth Management LLC - MarketBeat
Aventus Investment Advisors Inc. Boosts Stock Holdings in Meta Platforms, Inc. $META - MarketBeat
This Meta stock stat doesn't make sense after the Muse mic drop - Yahoo Finance
Meta loses New Mexico Facebook trial as jury finds 43.9 million violations - PPC Land
At Meta Connect, the company’s smart glasses were everywhere - TechCrunch
Santa Fe jury finds 43 million violations by Meta in state's second court win - santafenewmexican.com
This TSX top gainer rose 13% this week as it looks to ride Meta's wave - Financial Post
Elder Fraud Risk And Pleading Lessons From Meta Cases - Law360
Meta's AI tools, leadership boost bullish case, market expert says - marketscreener.com
New Mexico jury finds Facebook liable for deceiving users about privacy protections - NBC Bay Area
Meta Platforms (NASDAQ:META) Stock Price Down 3.3%What's Next? - MarketBeat
Meta misled users about Facebook data practices, New Mexico jury finds - Reuters
Facebook loses high-profile case in New Mexico over deceiving users (META:NASDAQ) - Seeking Alpha
Potential $219 billion penalty: Jury finds Meta misled New Mexicans 43.9 million times - New Mexico Political Report
META Stock Drops 3.4%: Meta Reportedly Moves To Strengthen Safety Alerts After Muse Security Issue Discovery - TradingView
Meta Stock Hits $779.82 High on Muse AI Launch [2026] - shattered.io
Meta Platforms Loses New Mexico Jury Trial Over Cambridge Analytica Data Scandal - marketscreener.com
Market Chatter: Meta Platforms Loses New Mexico Jury Trial Over Cambridge Analytica Data Scandal - Yahoo! Finance Canada
Meta’s Facebook found liable for deceiving users in Cambridge Analytica scandal - New York Post
AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street - Benzinga
How Meta’s Muse Saved the Market—While Savaging These Stocks - Barron's
Meta Stock Surges 11% on AI Monetization Hopes - Barchart.com
Meta’s Loudest AI Bull Just Cut His Own Stock Exposure and It Is Not Because of AI - Yahoo Finance
Attorney General seeks larger share of money from Meta deal - roanoke.com
Temu’s $962M Meta Ad Network Collapsed After Fake-Account Report - Yahoo Finance
Is Meta the Best Magnificent Seven Stock to Buy After Its AI Agent Topped the App Store? - The Motley Fool
Meta said to boost Muse safety warning after vulnerability - Breakingthenews.net
Meta Loses New Mexico Jury Trial Over Cambridge Analytica Data - Bloomberg Law News
Meta jury finds company misled New Mexico residents - Investing.com
As Meta Platforms Launches New VR Glasses, This Is How You Should Play META Stock - Yahoo Finance
Meta Stock Rally: Buy, Sell, or Hold? What to Do With Shares Now. - Barron's
Why Meta Stock Could Spike if It Crosses This Price Target - Barron's
Meta Vs. Alphabet: The Agentic AI Each Builds Will Be Very Different in 2027 - 247wallst.com
Meta Platforms' Muse Tracking Ahead of Recent AI App Launches, Deutsche Bank Says - marketscreener.com
Meta is putting its muscle behind Muse as the AI app takes off - TechCrunch
Meta, Levi's, Micron, Nike and more analyst calls of the week - Proactive financial news
Why is Meta Platforms stock sliding today? - Investing.com
Meta Just Got a Big New Partner for Its AI Glasses Push - ca.finance.yahoo.com
Your Meta AI Glasses Are Getting a Dolby Upgrade - Yahoo Finance
Finanzdaten der Meta Platforms Inc-Aktie (META)
Umsatz
Nettogewinn
Free Cashflow
ENV
Meta Platforms Inc-Aktie (META) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cox Christopher K | Chief Product Officer |
Sep 21 '26 |
Sale |
712.76 |
40,000 |
28,510,260 |
184,516 |
| Olivan Javier | Chief Operating Officer |
Sep 21 '26 |
Sale |
680.27 |
946 |
643,535 |
9,770 |
| Olivan Javier | Chief Operating Officer |
Sep 21 '26 |
Sale |
680.27 |
629 |
427,890 |
1,175 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):